Redirecting therapeutic T cells against myelin-specific T lymphocytes using a humanized myelin basic protein-HLA-DR2-zeta chimeric receptor.
Therapies that Ag-specifically target pathologic T lymphocytes responsible for multiple sclerosis (MS) and other autoimmune diseases would be expected to have improved therapeutic indices compared with Ag-nonspecific therapies. We have developed a cellular immunotherapy that uses chimeric receptors...
Auteurs principaux: | Moisini, I, Nguyen, P, Fugger, L, Geiger, T |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2008
|
Documents similaires
-
Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice.
par: Kort, J, et autres
Publié: (2006) -
Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.
par: Fridkis-Hareli, M, et autres
Publié: (2001) -
Mitochondrial recruitment in myelin: an anchor for myelin dynamics and plasticity?
par: Jean-David M Gothié, et autres
Publié: (2024-01-01) -
Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice.
par: Rich, C, et autres
Publié: (2004) -
Targeted Overexpression of a Golli-Myelin Basic Protein Isoform to Oligodendrocytes Results in Aberrant Oligodendrocyte Maturation and Myelination
par: Erin C Jacobs, et autres
Publié: (2009-08-01)